Prediction of Symptomatic Embolism in Filipinos With Infective Endocarditis Using the Embolic Risk French Calculator

Jaime Alfonso M. Aherrera, Maria Teresa B. Abola, Maria Margarita O. Balabagno, Lauro L. Abrahan IV, Jose Donato A. Magno, Paul Ferdinand M. Reganiti, Felix Eduardo R. Punzalan

Abstract

Background: Cardioembolic events are life-threatening complications of infective endocarditis (IE). The embolic risk French calculator estimates the embolic risk in IE computed on admission. Variables in this tool include age, diabetes, atrial fibrillation, prior embolism, vegetation length, and Staphylococcus aureus on culture. A computed risk of > 7% was considered high in the development of this tool. Knowledge of this risk applied in our local setting is important to guide clinicians in preventing such catastrophic complications. Among patients with IE, we aim to determine the efficacy of the embolic risk French calculator, using a computed score of > 7%, in predicting major embolic events.

Methods: All adults admitted from 2013 to 2016 with definite IE were included. The risk for embolic events was computed on admission. All were monitored for the duration of admission for the occurrence of the primary outcome (any major embolic event: arterial emboli, intracranial hemorrhage, pulmonary infarcts, or aneurysms). Secondary outcomes were: 1) composite of death and embolic events; and 2) death from any cause.

Results: Eighty-seven adults with definite IE were included. Majority had a valvular heart disease and preserved ejection fraction (EF). The mitral valve was most commonly involved. Embolic events occurred in 25 (29%). Multivariate analysis identified a high embolic score > 7% (relative risk (RR): 15.12, P < 0.001), vegetation area ≥ 18 mm² (RR: 6.39, P < 0.01), and a prior embolism (RR: 5.18, P = 0.018) to be independent predictors of embolic events. For the composite of embolic events and death, independent predictors include a high score of > 7% (RR: 13.56, P < 0.001) and a prior embolus (RR: 13.75, P = 0.002). Independent predictors of death were a high score > 7% (RR: 6.20, P = 0.003) and EF ≤ 45% (RR: 9.91, P = 0.004).

Conclusion: Cardioembolic events are more prevalent in our study compared to previous data. The embolic risk French calculator is a useful tool to estimate and predict risk for embolic events and in-hospital mortality. The risk of developing embolic events should be weighed against the risks of early preventive cardiac surgery, as to institute timely and appropriate management.

Keywords: Endocarditis; Echocardiography; Embolism; Risk calculator

Introduction

Infective endocarditis (IE) is an evolving disease. Advances in medical science have provided new insights to its pathophysiology, diagnosis, and treatment. However, even with the availability of advanced diagnostic techniques, improved antimicrobial chemotherapy, and potentially curative surgery, IE has a persistently high mortality and morbidity and has remained unchanged over the past two decades and may even be increasing [1]. One of the more catastrophic complications of IE is the occurrence of cardioembolic events to the major systems of the body, leading to adverse outcomes. They are believed to be due to fragmentation of vegetations, the prototypical lesion in IE. Risk factors for cardioembolism were identified in several reviews, but there is paucity of data in the local setting. Knowledge of these risk factors is of utmost importance to guide clinicians in prompt management to prevent such catastrophic complications.

There are two types of cardioembolic events based on duration: 1) events occurring before initiation of antibiotics, which may be prevented by early initiation of antibiotics; and 2) events that occur during or after antibiotic therapy, which may be prevented by early valve surgery. For the purposes of this study, we will focus on the predictors of embolic events that occur during antibiotic therapy. We emphasize that the evaluation of the embolic risk upon admission is critical in management of IE to institute prompt and appropriate interventions.

Echocardiography and cardioembolic events

Echocardiographic characteristics of the vegetation, the prototypical lesion in IE, have been shown in several studies to predict cardioembolic events. Of the predictors reported, the
most frequently used were the vegetation length and/or area, mobility, and location. In a recent meta-analysis [2], the major determinant of embolic risk is the size of the vegetation, which was also included in the embolic risk French calculator. Studies in the past have varying lengths to define a “large vegetation” that is prone to embolize, but most literature would classify a vegetation length of 10 - 15 mm as “large”.

The embolic risk French calculator

Hubert et al developed and validated a calculator to quantify the embolic risk of patients with endocarditis on admission [3]. The aim of their study was to develop and validate a simple calculator to quantify the embolic risk at admission of patients with IE. Eight hundred forty-seven patients with definite endocarditis were included with the primary end-point of symptomatic embolism after the initiation of antibiotic therapy up to 6 months. These events were defined as sudden clinical symptoms of cerebral ischemia or peripheral or pulmonary embolism, confirmed by corresponding imaging. Six variables were associated with embolic risks and were used to create the calculator: age, diabetes, atrial fibrillation (AF), embolism before antibiotics, vegetation length, and Staphylococcus aureus infection. The predictive accuracy of the calculator was assessed by studying the agreement between predicted embolic risk and observed embolic risk, which showed that the calibration of the model was excellent. This tool is a validated simple bedside prediction system that can be used to quantify the embolic risk at admission of patients with IE. The second part of this study validated that a high embolic risk (defined as > 7% risk) was associated with embolic events.

Table 1. Definition of Variables

| Variables collected                  | Definition/description                                                                 |
|--------------------------------------|----------------------------------------------------------------------------------------|
| Presence of minor emboli on admission| Any minor embolic events present on admission, before the initiation of antibiotic therapy, such as Janeway lesions, Roth spots, splinter hemorrhages, petechial hemorrhages, and subconjunctival hemorrhage. |
| Presence of major emboli on admission| Any major embolic events present on admission, before the initiation of antibiotic therapy, further defined below. |
| Organism on blood culture            | Organism present on at least two sets of blood cultures                                |
| Presence of atrial fibrillation      | Persistent or transient atrial fibrillation documented on 12-lead electrocardiogram or on a cardiac monitor. |
| Length of vegetation                 | Vegetation length measured in various planes and the maximal length was recorded. For multiple vegetations, the largest length was used for analysis. A vegetation length ≥ 10 mm is considered to be a large vegetation. |
| Area of vegetation                   | Computed by the longest length multiplied by the widest width of a single vegetation. For multiple vegetations, the individual computed areas were added. An area of ≥ 18 mm² is considered to be a large vegetation. |
| Ejection fraction                    | Echocardiographically derived by the Teicholz method. For studies with wall motion abnormalities, the EF derived by Simpson’s method was recorded. |
| Significant valvular regurgitation    | Defined as a “severe” regurgitant lesion (e.g., severe MR, severe TR).                 |
| Location of vegetation               | Left-sided vegetations pertain to those located on the left side of the heart, including the MV, AV, endocardium of the LA or LV, or aorta. Right-sided vegetations pertain to those located on the right side, including the TV, PV, endocardium of the RA or RV, or the pulmonary artery. |
| Prosthetic valve vegetation          | Includes mechanical or bioprosthetic valves.                                           |

Significance of the study

Our study will determine the predictors of cardioembolic events. This study will also validate the embolic risk French calculator in predicting major embolic events in the local setting. Knowledge of this fatal complication is of paramount importance because early surgical intervention may be lifesaving, as long as the benefit from high-risk surgery would outweigh the risk of major embolic arterial events.

Research question

Among patients with definite IE admitted at the Philippine General Hospital (PGH) from 2013 to 2016, is a high computed embolic risk (> 7%) using the embolic risk French calculator on admission correlated with the occurrence of major cardioembolic events?

Objectives

The general objective was to determine the efficacy of a high embolic risk (> 7%) computed using the embolic risk French calculator in predicting major cardioembolic events among patients with definite infective endocarditis admitted at the University of the Philippines-Philippine General Hospital (UP-PGH) from March 2013 to January 2016.
The specific objectives were to describe the clinical, microbiologic, and echocardiographic profile of adult patients with IE admitted at the UP-PGH; to describe the minor and major embolic in-hospital events of adult patients admitted for IE (minor embolic events include splinter hemorrhage, Janeway lesions, Roth spots, or petechial and conjunctival hemorrhage; major embolic events include any arterial emboli, intracranial hemorrhage, pulmonary infarcts, or mycotic aneurysms); and to determine the association of a high-risk embolic risk score > 7% (as computed by the embolic risk French calculator) with outcomes within a period of 1 month after the initiation of antibiotic therapy (primary outcome: major embolic events; composite of embolic events and death; death from any cause).

**Methods**

**Study design, setting, and study population**

The study was conducted at the UP-PGH. Data were collected by chart review of admitted patients at the service and pay wards of the UP-PGH from March 2013 to January 2016. Adult patients with definite IE, based using the modified Duke’s criteria, were included. The protocol was submitted to the UPMREB for ethics review and approval.

**Data collection**

All patients with definite IE using the modified Duke’s criteria were included. The clinical, microbiologic, and echocardiographic data were gathered and recorded. The risk of the patients for embolic events was computed on admission using the French calculator, available online. Data included in the calculator include age, diabetes, AF, major embolism prior to antibiotic therapy, vegetation length on echocardiography, and *Staphylococcus aureus* on blood culture. After encoding these variables in the calculator, the risk for cardioembolic events was provided. In this study, a high score was defined as an embolic risk score of > 7% based on the validation study of Hubert et al. Tables 1 and 2 define the variables collected.

**Outcomes**

The occurrence of in-hospital major embolic events was determined (i.e. arterial emboli, intracranial hemorrhage, pulmonary infarcts, or mycotic aneurysms not attributable to any other etiology other than endocarditis). These major embolic events were diagnosed based on symptoms and/or imaging modalities. The table below defines the outcomes monitored. Other outcomes were: 1) the composite of death and embolic events; 2) death from any cause.

**Statistical analysis**

Descriptive analysis was done by obtaining the mean and standard deviation of quantitative variables. Proportions and frequencies were reported for qualitative variables. For quantitative variables, *t*-test of two independent samples was used to determine if there is a significant difference. For categorical variables, the Z-test was used. The logistic regression analysis was used to find correlation between the computed risk for embolic events and other echocardiographic parameters and the subsequent development of embolic events with and/or without adjustments of potentially confounding baseline variables. A P-value of < 0.25 was considered as statistically significant. All significant variables were included in the final model of multivariate analysis.

**Results**

**Baseline characteristics**

A total of 106 patients with endocarditis were screened, but 19 were excluded due to a diagnosis of “possible IE”. Eighty-seven
(87) patients with a mean age of 40 years old with definite endocarditis were included. Table 3 summarizes the baseline characteristics of our patients stratified by the development of the primary outcome (major embolic events). The mean duration of illness prior to admission was 7 weeks. Majority complained of fever, worsening or development of heart failure symptoms, and edema. On admission, the most common physical examination findings were fever, signs of heart failure, and a murmur. The most common co-morbidities were diabetes mellitus, hypertension, and tuberculosis. Majority of patients had valvular and congenital heart disease as a predisposing endocardial disease (Table 4). Twenty-four (24) patients (28%) were in AF (or had intermittent AF) documented on electrocardiogram, while the rest were in sinus rhythm. Most had negative blood cultures, but the most common organism isolated was Streptococcus viridans (24%). Staphylococcus spp. was detected in 15%. The most common antibiotics used were gentamycin, ceftriaxone, and vancomycin. Medical therapy for heart failure and other complications were administered as well.

### The embolic risk French calculator

Components of the embolic risk French calculator include age, presence of diabetes, major emboli on admission, AF, vegetation length ≥ 10 mm on echocardiography, and Staphylococcus aureus on blood culture. Table 5 summarizes the variables and breakdown of the components included in the French calculator. Of note, a vegetation length ≥ 10 mm on echocardiography was the most frequent variable present in our database. Among those who developed embolic events, the proportion of those with major emboli prior to admission, AF, large vegetations (≥

---

### Table 3. Baseline Clinical Profile Stratified by Outcome (Development of Embolus)

| Variable                                | Total (n = 87) (%) | With embolus* (n = 25) (%) | Without embolus (n = 62) (%) | P-value |
|-----------------------------------------|-------------------|----------------------------|----------------------------|---------|
| Age (mean ± SD)                         | 39.90 (13.98)     | 36.68 (11.40)              | 41.19 (14.78)               | 0.175   |
| > 55 years old                         | 15 (17.24)        | 2 (8.00)                   | 13 (20.97)                  | 0.147   |
| ≤ 55 years old                         | 72 (82.76)        | 23 (92.00)                 | 49 (79.00)                  |         |
| Male sex                                | 49 (56.32)        | 16 (64.00)                 | 33 (53.23)                  | 0.359   |
| Presence of minor emboli on admission**| 44 (50.57)        | 15 (60.00)                 | 29 (46.77)                  | 0.264   |
| Mean duration of illness in weeks       | 7.21 (7.75)       | 5.00 (5.41)                | 8.10 (8.38)                 | 0.092   |
| < 6 weeks (acute-subacute)              | 57 (65.51)        | 19 (76.00)                 | 38 (61.29)                  | 0.191   |
| ≥ 6 weeks (chronic)                    | 30 (34.48)        | 6 (24.00)                  | 24 (38.71)                  |         |
| Organism on blood culture               |                   |                            |                            |         |
| Staphylococcus spp.                    | 13 (14.94)        | 7 (28.00)                  | 6 (9.68)                    | 0.030   |
| Streptococcus viridans                 | 21 (24.14)        | 7 (28.00)                  | 14 (22.58)                  | 0.593   |
| Gram negative bacteria                 | 11 (12.64)        | 3 (12.00)                  | 8 (12.90)                   | 0.909   |
| Culture negative                       | 40 (45.98)        | 8 (32.00)                  | 32 (51.61)                  | 0.097   |

*Development major embolism after initiation of antibiotic therapy. **Minor embolic events include splinter hemorrhage, Janeway lesions or conjunctival hemorrhage.

### Table 4. Distribution According to Predisposing Cardiac Condition by Echocardiography

| Predisposing cardiac condition                  | Frequency (n = 87) (%) |
|------------------------------------------------|-----------------------|
| Valvular heart disease (rheumatic and non-rheumatic) | 59 (68%)              |
| Mitral stenosis                                 | 25                    |
| Mitral valve prolapse                           | 14                    |
| Aortic stenosis                                 | 9                     |
| Congenital heart disease (CHD)                  | 15 (17%)              |
| Ventricular septal defect                       | 8                     |
| Patent ductus arteriosus                        | 3                     |
| Repaired CHD                                    | 2                     |
| Pulmonic stenosis                               | 1                     |
| Prosthetic valve endocarditis                    | 5 (7%)                |
| Unknown or no underlying predisposition          | 8 (11%)               |
and Staphylococcus aureus was more frequent. The mean score derived from the French calculator was significantly higher among those who developed embolic events (8.68% vs. 3.69%, P < 0.001).

**Echocardiographic profile of patients included**

The systolic function was generally preserved in our sample, with a mean ejection fraction (EF) of 61%. Only a small percentage (13%) had a depressed EF of ≤ 45%. The most common valve involvement (of vegetations) was the mitral (64%), followed by the aortic valve (24%). Involvement of the tricuspid and/or pulmonic valve was uncommon (9%). Severe regurgitant lesions were seen in 45%. As mentioned, majority had an underlying valvular heart disease, most common of which were mitral valve prolapse, mitral regurgitation, and mitral stenosis. Among those with congenital heart diseases, common defects included ventricular septal defect, valvular lesions, and a patent ductus arteriosus. Prosthetic valve endocarditis was diagnosed in only three patients (3%). In 19 patients, a transesophageal echocardiogram was needed to confirm the diagnosis of endocarditis. Majority had at least one vegetation documented (74%), while some had multiple vegetations (21%). Majority of the vegetations were less than 10 mm in longest length (57%), while only 16% had a vegetation ≥ 15 mm in length. The area of the vegetation was computed by multiplying the longest length and the widest width. Our sample had a mean vegetation area of 70.4 mm² and majority (57%) had an area of ≥ 18 mm² (value of significance in some studies reviewed). Table 6 summarizes the echocardiographic profile of our patients, stratified by the development of the primary outcome (major embolic event).

**Table 5. Components of the French Risk Calculator**

| Variable                                      | Total (n = 87) (%) | With embolus* (n = 25) (%) | Without embolus (n = 62) (%) | P-value |
|-----------------------------------------------|-------------------|-----------------------------|-----------------------------|---------|
| Mean age (SD)                                 | 39.86 (13.95)     | 36.72 (11.39)               | 41.13 (14.75)               | 0.183   |
| Presence of diabetes mellitus                 | 18 (20.69)        | 6 (24.00)                   | 12 (19.35)                  | 0.628   |
| Major emboli prior to admission               | 18 (20.69)        | 11 (44.00)                  | 7 (11.29)                   | 0.001*  |
| Atrial fibrillation                           | 23 (26.44)        | 12 (48.00)                  | 11 (17.74)                  | 0.004*  |
| Length of vegetation on 2D echocardiogram    |                   |                             |                             |         |
| < 10 mm                                       | 51 (58.62)        | 7 (28.00)                   | 44 (70.97)                  | < 0.001*|
| ≥ 10 mm                                       | 35 (40.23)        | 18 (72.00)                  | 17 (27.42)                  | < 0.001*|
| Staphylococcus aureus on blood culture        | 8 (9.20)          | 6 (24.00)                   | 2 (3.23)                    | 0.002*  |
| Mean score on French calculator (SD)          | 5.13 (4.33)       | 8.68 (5.75)                 | 3.69 (2.48)                 | < 0.001*|

*Major embolic events included any arterial emboli, intracranial hemorrhage, pulmonary infarcts, or mycotic aneurysms. *P value < 0.05.

Description of the minor and major embolic events encountered in the study

Minor and major emboli were present on admission in 51% and 30%, respectively. Minor emboli included subconjunctival hemorrhage (37%), Janeway lesions (22%), Roth spots (14%), splinter hemorrhages (8%), and non-specific rashes or petechiae were seen in 34%. Seventeen (17) patients had major embolic events prior to therapy (i.e., present on admission). Twenty-five (25) patients had new embolic events during the course of therapy (primary outcome). Common sites of major embolism were the CNS, pulmonary, and renal vasculature. Figure 1 summarizes the distribution of these embolic events. Of note, six patients had embolic events in more than one organ system.

**Primary endpoint: predictors of major embolic events during admission**

Major embolic events after the initiation of antibiotic therapy developed in 25 patients (29%). Majority occurred during the first week of antibiotic therapy (47%). Among those who eventually developed an embolus at 1 month (primary outcome), the proportions of those who had a previous major embolus on admission and AF on electrocardiogram were higher, compared to those who did not have an embolism at 1 month. Those who had a major embolus during the course also had larger vegetations (length ≥ 10 mm and/or area ≥ 18 mm²) on 2D echocardiogram, compared to those who did not develop embolic events. Of note, the mean embolic risk French score computed in the calculator was higher among those who developed a cardioembolism compared to those who did not develop a cardioembolism (8.7% vs. 3.7%, respectively). Other than the vegetation length and area, the other echocardiographic parameters did not statistically differ among the two groups: those who had embolic events had more participants with a vegetation length ≥ 10 mm and area ≥ 18 mm².

All patients were classified according to the value of their embolic risk predicted by the calculator at 1 month after initiation of antibiotic therapy (high versus low risk). Two groups were formed: greater than 7% vs. ≤ 7%. This was the
cut-off value validated by Hubert et al. Univariate analysis (Table 7) was done and identified significant variables associated with the occurrence of embolic events: high computed risk for embolic events (> 7%), embolism prior to admission, AF, vegetation size on echocardiography (length ≥ 10 mm and/or area ≥ 18 mm²), and *Staphylococcus aureus* on blood culture. Of these, multivariate analysis (Table 8) identified a high computed embolic risk French score (> 7%), a vegetation area of ≥ 18 mm², and the presence of an embolism prior to initiation of medical therapy to be significant and independent predictors of embolic events. The risk of having a major embolic event among those with a high computed embolic risk using the French calculator (> 7%) is 15.1 times higher than those with a low computed score (relative risk (RR): 14.1, P < 0.001).

### Secondary endpoints: composite of embolic events and death during admission

Secondary endpoints tested include a composite of death and embolic events and death from any cause. Thirty-seven patients (43%) had the outcome of composite of death and embolic events. There were 25 mortalities (29%) in our sample population. The most common cause of death in our data was presumed to be sequelae of cardioembolic events such as brain
herniation from CNS emboli or intracranial hemorrhage, respiratory failure from pulmonary emboli, or sepsis from solid organ abscesses. Other causes of death were heart failure, fatal arrhythmias, and sepsis. Figure 2 illustrates the causes of death in our patients.

For the composite of major embolic events and death, significant independent predictors on multivariate analysis include a high computed score > 7% (RR: 13.56, CI: 3.20 - 57.5, P < 0.001) and a major embolus prior to admission (RR: 13.75, CI: 2.55 - 74.11, P = 0.002). Significant independent predictors of death from any cause on multivariate analysis are a high computed score > 7% (RR: 6.20, CI: 1.89 - 20.32, P = 0.003) and a 2D echocardiographically derived EF ≤ 45% (RR: 9.91, CI: 2.11 - 46.63, P = 0.004). Table 9 summarizes the significant predictors on multivariate analysis for primary (discussed above) and secondary outcomes.

### Discussion

### Embolic events in endocarditis

Embolic events in endocarditis are frequent and life-threatening complications, believed to be caused by fragmentation of vegetations [4]. Major embolic events include arterial emboli, intracranial hemorrhage, pulmonary infarcts, or mycotic aneurysms; while minor embolic events include splinter hemorrhage, Janeway lesions or conjunctival hemorrhage. In a local retrospective study by Javier et al in 2009 of 91 patients with definite endocarditis, vascular manifestations included Roth spots (1%), splinter hemorrhages (1%), and Janeway lesions (1%) [5]. Another retrospective study by Pasaporte and Pena from 1979 to 2001 included 239 patients.

### Table 7. Univariate Analysis to Predict Development of Embolic Events during Admission

| Variable                                      | Relative Risk | 95% CI       | P-value  |
|-----------------------------------------------|---------------|--------------|----------|
| High risk for embolic events (> 7%)*         | 20.27         | 5.95 - 69.05 | < 0.001* |
| Age > 55                                      | 0.33          | 0.07 - 1.57  | 0.163    |
| Diabetes mellitus                             | 1.04          | 0.32 - 3.34  | 0.945    |
| Minor embolism prior to therapy               | 1.71          | 0.66 - 4.38  | 0.266    |
| Major embolism prior to therapy               | 8.62          | 2.73 - 27.23 | < 0.001* |
| Atrial fibrillation                           | 3.85          | 1.41 - 10.52 | 0.009*   |
| Ejection fraction < 45%                       | 2.33          | 0.64 - 8.49  | 0.199    |
| Left-sided vegetation                         | 0.36          | 0.08 - 1.58  | 0.176    |
| More than one vegetation                      | 1.80          | 0.61 - 5.36  | 0.289    |
| Vegetation length ≥ 10 mm                     | 4.02          | 1.51 - 10.71 | 0.005*   |
| Vegetation length ≥ 15 mm                     | 2.13          | 0.65 - 6.94  | 0.209    |
| Area of vegetation ≥ 18 mm²                   | 5.97          | 1.84 - 19.44 | 0.003*   |
| *Staphylococcus aureus* on culture           | 3.63          | 1.08 - 12.21 | 0.037*   |

*Included in the final model of multivariate analysis. *High risk embolic events using the embolic risk French calculator were set at > 7% risk at 1 month (see references).
Vascular manifestations included splinter hemorrhages (4%), Janeway lesions (2%), Roth spots (1%), and embolic phenomenon (6%) [6].

Our data, collected prospectively, showed a higher prevalence of minor and major vascular events. Consistent with available literature, the most common site of major embolic events in our study was still the CNS, manifesting as neurologic deficits, headache, dizziness, seizures, or loss of consciousness. Pulmonary embolism manifested as hemoptysis, sudden respiratory failure, and/or hypoxemia. Renal and splenic emboli manifested as abdominal pain or tenderness, documented by ultrasound in most cases (autopsy in one case). Embolism to the eye(s) was seen in two patients, which manifested as endophthalmitis. Aneurysms occurred in three patients (mycotic aneurysm in two, and celiac aneurysm in another). Of note, the occurrence of embolic events was associated with in-hospital mortality [7].

Echocardiographic predictors of major embolic events in endocarditis

Advances in echocardiographic techniques have brought about a better understanding of the correlation between the echocardiographic characteristics of the vegetation and incidence of complications. Predictors of the occurrence of embolic events and its prognostic influence were also reviewed by Fabri et al [8] among 629 patients with left-sided endocarditis. Among this population, 133 patients had embolic events. Embolic events were higher in S. aureus IE, mitral or aortic prosthetic valve endocarditis, and vegetations on echocardiography. They were lower in those with a longer duration of symptoms. The presence of embolic events also doubled the risk of mortality in this population. Di Salvo et al [9], in their review of 178 patients with IE (66 of whom had embolic events), concluded that the only predictors of embolism were vegetation length (> 15 mm). There was no difference between patients with and without embolism in terms of age, gender and left valve involved. Contrary to traditional knowledge, another review by De Castro et al [10] concluded that there were no differences in any of the echocardiographic characteristics of embolic events.

The vegetation size seems to be the most studied and most consistent echocardiographic parameter with regard to predictors of cardioembolic events. In our review of literature, there are two methods to describe vegetation size: 1) vegetation length (mm), and 2) vegetation area (mm²). A large vegetation would usually pertain to a vegetation that is more than 10 - 15 mm in length, which is a predictor of cardioembolic events in IE. In a systematic review of Okonta and Adamu [11] involving 16 papers, a vegetation length of ≥ 10 mm is an indication for surgery. A study by Kjaergaard et al [12] found that vegetation area performed better than the vegetation length in predicting adverse. Since it is not routine for cardiologists to measure the size of vegetation using the area (mm²), this finding may encourage its utility in IE patients. Our study has demonstrated that a vegetation length > 10 mm (as a component of the French embolic risk score) and a vegetation area ≥ 18 mm² are two useful parameters to identify those who are at risk for embolic events during antibiotic therapy.

The embolic risk French calculator

The vegetation length and the presence of a previous embolism are the only two parameters included in the present international guidelines to assess embolic risk and indicate preventive valve surgery [13, 14]. As mentioned in the paper of Hubert et al, these recommendations do not provide a precise quantifica-
tion of embolic risk and do not take into account other poten-
tially important predictors. The embolic risk French calcu-
lator, in addition to vegetation length and previous embolism,
also takes into account variables that were related to patient
characteristics (age, diabetes, and AF). This calculator focused
on predictors on admission, as these were the most important
factors in rapid therapeutic decisions to avoid embolic events.
Our data validated the use of the embolic risk French calcu-
lator to predict embolic events. Likewise, since embolic events
were related to mortality in IE, a high-risk score on the calcu-
lator was also a predictor of death.

Death and endocarditis

Among the 87 patients, 25 (29%) died before completing
the 28-day observation period. Majority of the deaths were
presumed to be sequelae of cardioembolic events, therefore,
embolic events should also be regarded as an indicator of
increased risk for mortality emphasizing the prognostic sig-
nificance of this complication. A previous paper by Aherrera
et al [8] for publication in the Philippine Journal of Cardiol-
ogy demonstrated that the occurrence of embolic events is
also a predictor of death (RR: 4.5, CI: 1.41-14.3, P = 0.011).
Our study has shown that a high embolic risk score using
the French calculator and a low EF during IE are predictors of
death from any cause.

Limitations of the study

It is important to note that the outcome of cardioembolism was
investigated only when presented with symptoms, therefore,
asymptomatic emboli may have been undetected. Imaging
modalities were not done in all patients; rather, they were guided
by the presence of symptoms. Therefore, microemboli caus-
ing minimal or no symptoms may have been undetected. In
addition, 25 patients (29%) died before the end of the 28-day
observation period; however, 12 of the 25 patients (48%) died
as a sequela of cardioembolism. Therefore, the outcome of car-
dioembolism may be underestimated due to the 13 deaths that
did not reach the 28th day of observation.

Given these limitations, we recommend that a larger, mul-
ticenter study be done that would have more precise outcome
assessors, such as standardized imaging (i.e., cranial CT or
MRI, abdominal CT, etc.) to be done to all patients at the end
of the observation period.

Conclusion

Major and minor embolic manifestations in endocarditis were
prevalent in our study. The most common site of major embo-
lish was the CNS. Emboli occur relatively early in the course
of IE, even during antibiotic therapy. The French risk calcu-
lator and echocardiography are useful tools to estimate the risk
for embolic events and death among patients with definite
endocarditis in our setting. Our study has demonstrated that
echocardiographic parameters such as a vegetation length ≥ 10
mm (as a component of the French embolic risk score) and a
vegetation area ≥ 18 mm² are two useful parameters to iden-
tify those who are at risk for embolic events during antibiotic
therapy. The risk for embolism in IE should be quantified at
admission using the specified predictors to make rapid ther-
apeutic decisions. This risk should be weighed against the risks
of early cardiac surgery during the active phase of endocardi-
tis, as to institute timely and appropriate management.

References

1. Prendergast BD. The changing face of infective endocar-
ditis. Heart. 2006;92(7):879-885.
2. Salehian O, Chan KL. Systemic embolism in endocardi-
tis: incidence, risk factors, clinical significance, and treat-
ment strategies. In: Chan KL, Embil JM. Endocarditis.
Diagnosis and Management. London: Springer-Verlag;
2006:229-240.
3. Hubert S, Thuny F, Resseguyer N, Giorgi R, Tribouilloy
C, Le Dolley Y, Casalta JP, et al. Prediction of sympto-
matism embolism in infective endocarditis: incidence, risk factors, clinical significance, and treat-
ment strategies. In: Chan KL, Embil JM. Endocarditis.
Diagnosis and Management. London: Springer-Verlag;
2006:229-240.
4. Thuny F, Habib G, Le Dolley Y, Canault M, Casalta JP,
Verdier M, Avierinos JF, et al. Circulating matrix metal-
loproteinases in infective endocarditis: a possible marker
of the embolic risk. PLoS One. 2011;6(4):e18830.
5. Javier D, et al. The changing face of infective endocardi-
tis in the Filipino: A six year review (2004-2009) at the
Philippine General Hospital. Unpublished.
6. Pasaporte BB, Pena AC. Association of infective endocar-
ditis with age: a 21 years experience. Philippine Journal
of Microbiology. 33:1.
7. Aherrera J, Balabagno M, et al. Risk of death and adverse
outcomes in adult Filipinos admitted for infective endocar-
ditis: A prospective cohort. Philippine Journal of Car-

Table 9. Multiple Logistic Regression to Predict Primary and Secondary Outcomes

| Variable | Embolic event (primary endpoint) | Composite of death and embolic events | Death |
|----------|----------------------------------|-------------------------------------|-------|
|          | RR | P-value | RR | P-value | RR | P-value |
| High risk score (> 7%)* | 15.12 | < 0.001 | 13.56 | < 0.001 | 6.2 | 0.003 |
| Vegetation area ≥ 18 mm² | 6.39 | 0.010 | NS | NS | |
| Emboli prior to admission | 5.18 | 0.018 | 13.75 | 0.002 | NS | |
| Ejection fraction ≤ 45% | NS | | NS | | 9.91 | 0.004 |

*High risk score pertains to a high embolic risk score at one month, calculated using the French calculator. RR: relative risk; NS: not significant.
8. Fabri J, Jr., Issa VS, Pomerantzef PM, Grinberg M, Barretto AC, Mansur AJ. Time-related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis. Int J Cardiol. 2006;110(3):334-339.

9. Di Salvo G, Habib G, Pergola V, Avierinos JF, Philip E, Casalta JP, Vailloud JM, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol. 2001;37(4):1069-1076.

10. De Castro S, Cartoni D, et al. Transthoracic and transesophageal echocardiographic findings of vegetative lesions are not predictive of subsequent embolic events in patients with active infective endocarditis. JASE. 1997;9:406.

11. Okonta KE, Adamu YB. What size of vegetation is an indication for surgery in endocarditis? Interact Cardiovasc Thorac Surg. 2012;15(6):1052-1056.

12. Kjaergaard J, Rasmussen R, Bruun N, et al. Vegetation length or area: which is the better predictor of outcome in infective endocarditis? Unpublished data.

13. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr., Bolger AF, Levison ME, Ferrieri P, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394-434.

14. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30(19):2369-2413.